drugset / Trial / NCT01821703
A Study of LY3045697 After Multiple Oral Dosing in Healthy Participants
RandomizedCrossoverDouble-blind
Summary
The purpose of this study is to investigate the safety and tolerability of LY3045697 after multiple doses and to determine how long LY3045697 remains in the body. Each participant is expected to complete 3 dosing periods. At least 7 days will pass between dosing periods.
Timeline
- Start
- 2013-05
- Primary completion
- 2013-09
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY3045697 | Unknown | 0.1 mg | Oral |
| Subject | LY3045697 | Unknown | 100 mg | Oral |
| Comparator | Spironolactone | Small molecule | 25 mg | Oral |
Indications
No indication recorded.